SYRE Enters Earnings Day With 16% Short Interest and an Activist at the Table
Spyre Therapeutics reports Thursday with a clinical-stage IBD pipeline, a substantial short position that has barely moved all month, and a named activist holding nearly 10% of the company. Short sellers have committed…